EA200400658A1 - Способ лечения опухолей, экспрессирующих рецептор для ил-13 (варианты) - Google Patents
Способ лечения опухолей, экспрессирующих рецептор для ил-13 (варианты)Info
- Publication number
- EA200400658A1 EA200400658A1 EA200400658A EA200400658A EA200400658A1 EA 200400658 A1 EA200400658 A1 EA 200400658A1 EA 200400658 A EA200400658 A EA 200400658A EA 200400658 A EA200400658 A EA 200400658A EA 200400658 A1 EA200400658 A1 EA 200400658A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- catheter
- receptor
- tumor
- options
- treatment
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Предложен способ лечения опухолей, которые экспрессируют рецептор для ИЛ-13. Способ предусматривает непосредственное введение в опухоль цитотоксина, который направлен на рецептор ИЛ-13. Цитотоксический агент может быть введен посредством доставки, усиленной конвекцией, через подходящий катетер или с помощью других средств. При использовании катетера с усиленной конвекцией способ включает помещение конца катетера, по меньшей мере, в непосредственной близости от опухоли. После того, как катетер помещен, его соединяют с насосом, который доставляет активный агент через конец катетера в опухоль. Во время инфузии поддерживают градиент давления на конце катетера.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33247701P | 2001-11-09 | 2001-11-09 | |
PCT/US2002/036112 WO2003039600A1 (en) | 2001-11-09 | 2002-11-08 | Selective treatment of il-13 expressing tumors |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200400658A1 true EA200400658A1 (ru) | 2004-10-28 |
Family
ID=23298400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200400658A EA200400658A1 (ru) | 2001-11-09 | 2002-11-08 | Способ лечения опухолей, экспрессирующих рецептор для ил-13 (варианты) |
Country Status (7)
Country | Link |
---|---|
US (1) | US20050002918A1 (ru) |
EP (1) | EP1448237A1 (ru) |
JP (1) | JP2005508375A (ru) |
CA (1) | CA2466443A1 (ru) |
EA (1) | EA200400658A1 (ru) |
IL (1) | IL161863A0 (ru) |
WO (1) | WO2003039600A1 (ru) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7262173B2 (en) * | 1997-03-21 | 2007-08-28 | Georgetown University | Chemosensitizing with liposomes containing oligonucleotides |
ATE413164T1 (de) * | 2000-11-09 | 2008-11-15 | Neopharm Inc | Sn-38-lipidkomplexe und verfahren zu ihrer verwendung |
WO2003030864A1 (en) * | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
US7138512B2 (en) * | 2002-04-10 | 2006-11-21 | Georgetown University | Gene SHINC-2 and diagnostic and therapeutic uses thereof |
WO2003102011A1 (en) * | 2002-05-29 | 2003-12-11 | Neopharm, Inc. | Method for determining oligonucleotide concentration |
US20060030578A1 (en) * | 2002-08-20 | 2006-02-09 | Neopharm, Inc. | Pharmaceutically active lipid based formulation of irinotecan |
AU2003296897A1 (en) * | 2002-08-20 | 2004-05-04 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
AU2003268087A1 (en) * | 2002-08-23 | 2004-03-11 | Ian Ma | Liposomal gemcitabine compositions for better drug delivery |
EP1613284A2 (en) * | 2003-02-11 | 2006-01-11 | Neopharm, Inc. | Manufacturing process for liposomal preparations |
WO2004087758A2 (en) * | 2003-03-26 | 2004-10-14 | Neopharm, Inc. | Il 13 receptor alpha 2 antibody and methods of use |
WO2005000266A2 (en) * | 2003-05-22 | 2005-01-06 | Neopharm, Inc. | Liposomal formulations comprising a combination of two or more active agents |
US20060078560A1 (en) * | 2003-06-23 | 2006-04-13 | Neopharm, Inc. | Method of inducing apoptosis and inhibiting cardiolipin synthesis |
JP4813364B2 (ja) | 2003-11-25 | 2011-11-09 | アメリカ合衆国 | 突然変異型抗cd22抗体および免疫複合体 |
PL3006458T3 (pl) | 2005-07-29 | 2018-05-30 | The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services | Zmutowane egzotoksyny Pseudomonas o zmniejszonej antygenowości |
WO2007075912A2 (en) * | 2005-12-22 | 2007-07-05 | Neopharm, Inc. | A system and method of administering a therapeutic material to brain tissue |
US8112292B2 (en) | 2006-04-21 | 2012-02-07 | Medtronic Navigation, Inc. | Method and apparatus for optimizing a therapy |
EP2068975A4 (en) * | 2006-08-08 | 2013-10-30 | Peak Biosciences Inc | CATHETER AND ARRAY FOR ANTIQUE THERAPY |
US8660635B2 (en) * | 2006-09-29 | 2014-02-25 | Medtronic, Inc. | Method and apparatus for optimizing a computer assisted surgical procedure |
US20080206139A1 (en) * | 2006-11-03 | 2008-08-28 | The Penn State Research Foundation | Delivery system for diagnostic and therapeutic agents |
WO2008115511A1 (en) * | 2007-03-20 | 2008-09-25 | Peak Biosciences, Inc. | Method for therapeutic administration of radionucleosides |
US8165658B2 (en) * | 2008-09-26 | 2012-04-24 | Medtronic, Inc. | Method and apparatus for positioning a guide relative to a base |
CN102655882B (zh) | 2009-09-11 | 2014-11-19 | 美国政府健康及人类服务部 | 具有降低的免疫原性的改进的假单胞菌外毒素a |
CA2886064A1 (en) * | 2012-10-19 | 2014-04-24 | The Regents Of The University Of California | Treating tumors of the central nervous system |
WO2015070210A1 (en) | 2013-11-11 | 2015-05-14 | Wake Forest University Health Sciences | Epha3 and multi-valent targeting of tumors |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4596792A (en) * | 1981-09-04 | 1986-06-24 | The Regents Of The University Of California | Safe vaccine for hepatitis containing polymerized serum albumin |
FR2523976B1 (fr) * | 1982-03-26 | 1985-08-30 | Pasteur Institut | Nouveau produit proteique, obtention et application comme medicament, en particulier immunoregulateur et antiallergique |
US4661913A (en) * | 1984-09-11 | 1987-04-28 | Becton, Dickinson And Company | Apparatus and method for the detection and classification of articles using flow cytometry techniques |
US4608251A (en) * | 1984-11-09 | 1986-08-26 | Pitman-Moore, Inc. | LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues |
US4601903A (en) * | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4892827A (en) * | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
EP0814159B1 (en) * | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US5328984A (en) * | 1991-03-04 | 1994-07-12 | The United States As Represented By The Department Of Health & Human Services | Recombinant chimeric proteins deliverable across cellular membranes into cytosol of target cells |
US5776457A (en) * | 1991-03-29 | 1998-07-07 | Genentech, Inc. | Antibodies to human PF4A receptor and compositions thereof |
US5366859A (en) * | 1991-10-31 | 1994-11-22 | Mitsubishi Petrochemical Co., Ltd. | Radioimmunoassay method |
CA2099883A1 (en) * | 1991-11-07 | 1993-05-08 | John A. Kink | Epitope mapping of the c33c region of hcv |
US5639641A (en) * | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
WO1995005864A1 (en) * | 1993-08-27 | 1995-03-02 | Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Convection-enhanced drug delivery |
US5491096A (en) * | 1993-12-27 | 1996-02-13 | Eli Lilly And Company | Antigen detection with affinity chromatography and parallel processing a control |
US5635599A (en) * | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
US20020031492A1 (en) * | 1995-03-15 | 2002-03-14 | Waldemar Debinski | Characterizing a brain tumor |
US6428788B1 (en) * | 1995-03-15 | 2002-08-06 | Penn State University | Compositions and methods for specifically targeting tumors |
US6518061B1 (en) * | 1995-03-15 | 2003-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
US5614191A (en) * | 1995-03-15 | 1997-03-25 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
US20010053371A1 (en) * | 1999-01-07 | 2001-12-20 | Waldemar Debinski | Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13 |
US6265150B1 (en) * | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
GB9512994D0 (en) * | 1995-06-26 | 1995-08-30 | Brf International | Method for quantitative measurement of an enzyme linked immunosorbent assay |
US5714352A (en) * | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US20030229040A1 (en) * | 1997-03-21 | 2003-12-11 | Georgetown University | Cationic liposomal delivery system and therapeutic use thereof |
US6559129B1 (en) * | 1997-03-21 | 2003-05-06 | Georgetown University | Cationic liposomal delivery system and therapeutic use thereof |
US6126965A (en) * | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
US7262173B2 (en) * | 1997-03-21 | 2007-08-28 | Georgetown University | Chemosensitizing with liposomes containing oligonucleotides |
US6090407A (en) * | 1997-09-23 | 2000-07-18 | Research Development Foundation | Small particle liposome aerosols for delivery of anti-cancer drugs |
US20030129132A1 (en) * | 1998-02-17 | 2003-07-10 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | IL-13 receptor specific chimeric proteins & uses thereof |
US6296843B1 (en) * | 1998-04-03 | 2001-10-02 | The Penn State Research Foundation | Mutagenized IL 13-based chimeric molecules |
US6884603B2 (en) * | 1998-04-03 | 2005-04-26 | The Penn State Research Foundation | Nucleic acids encoding IL13 mutants |
US6576232B1 (en) * | 1998-04-03 | 2003-06-10 | The Penn State Research Foundation | IL13 mutants |
US6630576B2 (en) * | 1998-04-03 | 2003-10-07 | Pennsylvania State Research Foundation | Amino acid substitution mutants of interleukin 13 |
US6461637B1 (en) * | 2000-09-01 | 2002-10-08 | Neopharm, Inc. | Method of administering liposomal encapsulated taxane |
US6146659A (en) * | 1998-07-01 | 2000-11-14 | Neopharm, Inc. | Method of administering liposomal encapsulated taxane |
EP1222212A4 (en) * | 1999-10-06 | 2005-05-04 | Penn State Res Found | MUTANTS OF IL-13 |
EP1257289A1 (en) * | 2000-02-08 | 2002-11-20 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
FR2809898B1 (fr) * | 2000-06-05 | 2002-11-29 | Cit Alcatel | Procede de gestion d'un reseau de telecommunications et unite de gestion de reseau pour la mise en oeuvre du procede |
JP2004511510A (ja) * | 2000-10-16 | 2004-04-15 | ネオファーム、インコーポレイティッド | ミトキサントロンのリポソーム製剤 |
ATE413164T1 (de) * | 2000-11-09 | 2008-11-15 | Neopharm Inc | Sn-38-lipidkomplexe und verfahren zu ihrer verwendung |
WO2002059337A1 (en) * | 2001-01-26 | 2002-08-01 | Georgetown University School Of Medicine | Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof |
US20020164624A1 (en) * | 2001-02-12 | 2002-11-07 | Waldemar Debinski | VEGF-D expression in brain cancer |
US20050260649A1 (en) * | 2001-02-12 | 2005-11-24 | The Penn State Research Foundation | Fra-1 expression in brain cancer |
AU2002258728A1 (en) * | 2001-04-06 | 2002-10-21 | Georgetown University | Gene brcc-3 and diagnostic and therapeutic uses thereof |
AU2002305151A1 (en) * | 2001-04-06 | 2002-10-21 | Georgetown University | Gene scc-112 and diagnostic and therapeutic uses thereof |
WO2002081639A2 (en) * | 2001-04-06 | 2002-10-17 | Georgetown University | Gene brcc2 and diagnostic and therapeutic uses thereof |
WO2003030864A1 (en) * | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
US20040136959A1 (en) * | 2001-08-15 | 2004-07-15 | Puri Raj K. | Sensitization of cancer cells to immunoconjugate-induced cell death by transfection with il -13 receptor alpha chain |
EP1455833A1 (en) * | 2001-12-04 | 2004-09-15 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES | Chimeric molecule for the treatment of th2-like cytokine mediated disorders |
CA2479306A1 (en) * | 2002-03-19 | 2003-10-02 | The Penn State Research Foundation | Egfr ligands and methods of use |
US7244565B2 (en) * | 2002-04-10 | 2007-07-17 | Georgetown University | Gene shinc-3 and diagnostic and therapeutic uses thereof |
US7138512B2 (en) * | 2002-04-10 | 2006-11-21 | Georgetown University | Gene SHINC-2 and diagnostic and therapeutic uses thereof |
US20050148528A1 (en) * | 2002-05-20 | 2005-07-07 | Neopharm, Inc | Method for reducing platelet count |
US20030228317A1 (en) * | 2002-05-22 | 2003-12-11 | Prafulla Gokhale | Gene BRCC-1 and diagnostic and therapeutic uses thereof |
CA2486967A1 (en) * | 2002-05-24 | 2003-12-04 | Neopharm, Inc. | Cardiolipin compositions their methods of preparation and use |
EA200401565A1 (ru) * | 2002-05-24 | 2005-04-28 | Неофарм, Инк. | Способ получения кардиолипина или аналога кардиолипина (варианты), способ получения липосомы и композиция кардиолипина для лечения заболеваний (варианты) |
WO2003102011A1 (en) * | 2002-05-29 | 2003-12-11 | Neopharm, Inc. | Method for determining oligonucleotide concentration |
AU2003296897A1 (en) * | 2002-08-20 | 2004-05-04 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
AU2003268087A1 (en) * | 2002-08-23 | 2004-03-11 | Ian Ma | Liposomal gemcitabine compositions for better drug delivery |
US20050277611A1 (en) * | 2002-10-16 | 2005-12-15 | Neopharm, Inc. | Cationic cardiolipin analoges and its use thereof |
-
2002
- 2002-11-08 IL IL16186302A patent/IL161863A0/xx unknown
- 2002-11-08 EA EA200400658A patent/EA200400658A1/ru unknown
- 2002-11-08 WO PCT/US2002/036112 patent/WO2003039600A1/en not_active Application Discontinuation
- 2002-11-08 EP EP02802899A patent/EP1448237A1/en not_active Withdrawn
- 2002-11-08 JP JP2003541890A patent/JP2005508375A/ja active Pending
- 2002-11-08 CA CA002466443A patent/CA2466443A1/en not_active Abandoned
-
2004
- 2004-05-10 US US10/842,189 patent/US20050002918A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2003039600A1 (en) | 2003-05-15 |
EP1448237A1 (en) | 2004-08-25 |
IL161863A0 (en) | 2005-11-20 |
JP2005508375A (ja) | 2005-03-31 |
CA2466443A1 (en) | 2003-05-15 |
US20050002918A1 (en) | 2005-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200400658A1 (ru) | Способ лечения опухолей, экспрессирующих рецептор для ил-13 (варианты) | |
DE602005011105D1 (de) | Implantierbare arzneiabgabevorrichtung mit drahtfäden | |
MX2009010000A (es) | Dispositivo para el suministro de farmaco. | |
CA2902713C (en) | Method and apparatus for drug delivery to a target site | |
EP1389121A4 (en) | METHODS AND COMPOSITIONS FOR TREATING MAMMARY NERVOUS TISSUE DAMAGE | |
SG161307A1 (en) | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases | |
CY1112403T1 (el) | Συσκευη, συστημα και μεθοδος για την χορηγηση σκληρυνομενου υλικου εντος οστου | |
WO2007127176A3 (en) | Ultrasound therapy system | |
WO2000032267A3 (en) | Device for locally delivering a drug in a body cavity | |
MXPA04003437A (es) | Dispositivo para suministro de medicamento por medio de iontoforesis o electroporacion intraocular. | |
IL212777A0 (en) | Baloon catheter | |
GB2435211B (en) | Drug delivery system | |
SI1913947T1 (sl) | Kombinirana terapija za zdravljenje raka | |
PH12020551715A1 (en) | Methods of treating cancer | |
EP1108426A3 (en) | Use of prostaglandin agonists to treat erectile dysfunction or impotence | |
MXPA02009984A (es) | Metodo y composicion para el tratamiento del cancer mediante la administracion de agentes quimioterapeuticos que inducen la apoptosis. | |
WO2006031390A3 (en) | Apparatus and methods for treating undesired veins | |
MX2019010651A (es) | Aparato y métodos para administración de un compuesto nauseogénico desde un dispositivo de administración de fármacos. | |
DE602005026510D1 (en) | Anthracyclinderivate | |
EP4233932A3 (en) | Apparatus for extracorporeal treatment of blood and method of priming an extracorporeal blood circuit | |
CN208525122U (zh) | 一种畜牧兽医注射器 | |
HK1050853A1 (en) | se of methoxymorpholino doxorubicin in the preparation of a medicament for the treatment of a liver tumor. | |
MY151447A (en) | Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke | |
Brastianos | Dabrafenib/trametinib | |
JP1725969S (ja) | 医療用マイクロシリンジユニット |